CNS diseasesMedherant is building a sustainable transdermal drug delivery company that generates value for patients, partners and investors by levering its unique TEPI Patch® technology. 

Medherant develops innovative transdermal and topical products to treat a wide range of diseases using its TEPI technology. We intend to license products we develop for commercialisation by others and to license our technology to third parties for whom we have formulated TEPI patch products.

Medherant has two potential long term sources of revenue – licence fees and royalties on sales of products developed with its proprietary TEPI technology. We currently receive fees for developing and testing TEPI patch formulations for third parties.